BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 15510624)

  • 1. Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases.
    Caly M; Genin P; Ghuzlan A A; Elie C; Fréneaux P; Klijanienko J; Rosty C; Sigal-Zafrani B; Vincent-Salomon A; Douggaz A; Zidane M; Sastre-Garau X
    Anticancer Res; 2004; 24(5B):3283-8. PubMed ID: 15510624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of tumor biological factors on survival in node-negative breast cancer.
    Harbeck N; Dettmar P; Thomssen C; Henselmann B; Kuhn W; Ulm K; Jänicke F; Höfler H; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2187-97. PubMed ID: 9703782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer.
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Breast Cancer Res Treat; 2005 May; 91(1):61-71. PubMed ID: 15868432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S-phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer - a multivariate study of 770 patients.
    Gazic B; Pizem J; Bracko M; Cufer T; Borstnar S; Pohar-Marinsek Z; Us-Krasovec M
    Cytopathology; 2008 Oct; 19(5):294-302. PubMed ID: 18070112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer].
    Moureau-Zabotto L; Bouchet C; Cesari D; Uzan S; Lefranc JP; Antoine M; Genestie C; Deniaud-Alexandre E; Bernaudin JF; Touboul E; Fleury-Feith J
    Cancer Radiother; 2005 Dec; 9(8):575-86. PubMed ID: 16243560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proliferative activity in primary breast carcinomas is a salient prognostic factor.
    Michels JJ; Marnay J; Delozier T; Denoux Y; Chasle J
    Cancer; 2004 Feb; 100(3):455-64. PubMed ID: 14745860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy.
    Vincent-Salomon A; Rousseau A; Jouve M; Beuzeboc P; Sigal-Zafrani B; Fréneaux P; Rosty C; Nos C; Campana F; Klijanienko J; Al Ghuzlan A; Sastre-Garau X;
    Eur J Cancer; 2004 Jul; 40(10):1502-8. PubMed ID: 15196533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma.
    MacGrogan G; Jollet I; Huet S; Sierankowski G; Picot V; Bonichon F; Coindre JM
    Mod Pathol; 1997 Aug; 10(8):769-76. PubMed ID: 9267818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up.
    Harbeck N; Dettmar P; Thomssen C; Berger U; Ulm K; Kates R; Höfler H; Jänicke F; Graeff H; Schmitt M
    Br J Cancer; 1999 May; 80(3-4):419-26. PubMed ID: 10408848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer cell kinetics: immunocytochemical determination of growth fractions by monoclonal antibody Ki-67 and correlation with flow cytometric S-phase and with some features of tumor aggressiveness.
    Gasparini G; Pozza F; Meli S; Reitano M; Santini G; Bevilacqua P
    Anticancer Res; 1991; 11(6):2015-21. PubMed ID: 1776834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
    Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
    Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative predictive value of three prognostic markers--S-phase fraction, PCNA and Mitotic count on axillary lymph node metastasis in carcinoma breast.
    Pervez S; Khan MN; Nasir MI
    J Ayub Med Coll Abbottabad; 2007; 19(1):3-5. PubMed ID: 17867469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction.
    Nordström B; Strang P; Bergström R; Nilsson S; Tribukait B
    Cancer; 1996 Nov; 78(9):1942-51. PubMed ID: 8909315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.
    Clark GM; Allred DC; Hilsenbeck SG; Chamness GC; Osborne CK; Jones D; Lee WH
    Cancer Res; 1997 Dec; 57(24):5505-8. PubMed ID: 9407959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA ploidy, S-phase fraction and mitotic indices as prognostic predictors of female breast cancer.
    Lipponen P; Papinaho S; Eskelinen M; Klemi PJ; Aaltomaa S; Kosma VM; Marin S; Syrjänen K
    Anticancer Res; 1992; 12(5):1533-8. PubMed ID: 1444217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies.
    Abele MC; Valente G; Kerim S; Navone R; Onesti P; Chiusa L; Resegotti L; Palestro G
    Haematologica; 1997; 82(3):281-5. PubMed ID: 9234572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer.
    Brown RW; Allred CD; Clark GM; Osborne CK; Hilsenbeck SG
    Clin Cancer Res; 1996 Mar; 2(3):585-92. PubMed ID: 9816207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
    Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
    Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometry in primary breast carcinomas: prognostic impact of multiploidy and hypoploidy.
    Michels JJ; Duigou F; Marnay J; Denoux Y; Delozier T; Chasle J
    Cytometry B Clin Cytom; 2003 Sep; 55(1):37-45. PubMed ID: 12949958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.